Table 3.
Immunohistochemical results for SOX4, SOX11, SOX9, and BCAT1 immunoreactivity in medulloblastoma, ependymoma, and control tissues
| Gene Expression | n | 0%–25% Weak | 25%–50% Moderate | 50%–75% Strong | 75%–100% Very Strong |
|---|---|---|---|---|---|
| SOX4 | |||||
| Medulloblastoma | 29 | 7% | 21% | 31% | 41% |
| Nonmetastatic | 25 | 8% | 24% | 28% | 36% |
| Metastasis | 4 | 0% | 0% | 50% | 50% |
| Ependymoma | 15 | 87% | 13% | 0% | 0% |
| Cellulare | 7 | 86% | 14% | 0% | 0% |
| Anaplastic | 8 | 88% | 13% | 0% | 0% |
| Cerebellum | 5 | 100% | 0% | 0% | 0% |
| Cortex | 5 | 100% | 0% | 0% | 0% |
| Normal ependyma | 5 | 100% | 0% | 0% | 0% |
| Plexus choroideus | 5 | 100% | 0% | 0% | 0% |
| SOX11 | |||||
| Medulloblastoma | 30 | 7% | 10% | 30% | 53% |
| Nonmetastatic | 24 | 8% | 8% | 29% | 54% |
| Metastasis | 6 | 0% | 17% | 33% | 50% |
| Ependymoma | 16 | 56% | 19% | 19% | 6% |
| Cellulare | 7 | 57% | 29% | 0% | 14% |
| Anaplastic | 9 | 56% | 11% | 33% | 0% |
| Cerebellum | 5 | 100% | 0% | 0% | 0% |
| Cortex | 5 | 100% | 0% | 0% | 0% |
| Normal ependyma | 5 | 100% | 0% | 0% | 0% |
| Plexus choroideus | 5 | 100% | 0% | 0% | 0% |
| SOX9 | |||||
| Medulloblastoma | 30 | 63% | 30% | 7% | 0% |
| Nonmetastatic | 25 | 60% | 32% | 8% | 0% |
| Metastasis | 5 | 80% | 20% | 0% | 0% |
| Ependymoma | 16 | 13% | 13% | 31% | 44% |
| Cellulare | 7 | 0% | 14% | 14% | 71% |
| Anaplastic | 9 | 22% | 11% | 44% | 22% |
| Cerebellum | 5 | 100% | 0% | 0% | 0% |
| Cortex | 5 | 100% | 0% | 0% | 0% |
| Normal ependyma | 5 | 100% | 0% | 0% | 0% |
| Plexus choroideus | 5 | 100% | 0% | 0% | 0% |
| BCAT1 | |||||
| Medulloblastoma | 34 | 62% | 12% | 18% | 9% |
| Nonmetastatic | 28 | 64% | 11% | 21% | 4% |
| Metastasis | 6 | 50% | 17% | 0% | 33% |
| Ependymoma | 5 | 100% | 0% | 0% | 0% |
| Cerebellum | 5 | 100% | 0% | 0% | 0% |
| Cortex | 5 | 100% | 0% | 0% | 0% |
| Normal ependyma | 5 | 100% | 0% | 0% | 0% |
| Plexus choroideus | 5 | 100% | 0% | 0% | 0% |